S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:FIXX

Homology Medicines Stock Forecast, Price & News

$11.26
+0.60 (+5.63 %)
(As of 09/22/2020 03:59 PM ET)
Add
Compare
Today's Range
$10.54
Now: $11.26
$11.26
50-Day Range
$9.94
MA: $11.11
$14.25
52-Week Range
$9.19
Now: $11.26
$22.50
Volume21,613 shs
Average Volume412,431 shs
Market Capitalization$509.15 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.25
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Read More
Homology Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$5.73 per share

Profitability

Net Income$-103,920,000.00
Net Margins-5,764.94%

Miscellaneous

Employees124
Market Cap$509.15 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$11.26
+0.60 (+5.63 %)
(As of 09/22/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

How has Homology Medicines' stock been impacted by COVID-19?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FIXX stock has decreased by 37.1% and is now trading at $11.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Homology Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Homology Medicines
.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Homology Medicines
.

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.04. The company earned $0.57 million during the quarter, compared to analyst estimates of $0.47 million. Homology Medicines had a negative net margin of 5,764.94% and a negative return on equity of 53.10%.
View Homology Medicines' earnings history
.

What price target have analysts set for FIXX?

7 analysts have issued twelve-month price objectives for Homology Medicines' stock. Their forecasts range from $27.00 to $34.00. On average, they expect Homology Medicines' share price to reach $30.43 in the next twelve months. This suggests a possible upside of 170.2% from the stock's current price.
View analysts' price targets for Homology Medicines
.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (9.62%), FMR LLC (4.94%), Bellevue Group AG (3.84%), Vanguard Group Inc. (3.25%), Cormorant Asset Management LP (1.22%) and Goldman Sachs Group Inc. (0.88%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am and W Bradford Smith.
View institutional ownership trends for Homology Medicines
.

Which institutional investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, and RTW Investments LP. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, James E Flynn, Timothy P Kelly, and W Bradford Smith.
View insider buying and selling activity for Homology Medicines
.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Vanguard Group Inc., Jacobs Levy Equity Management Inc., Point72 Asset Management L.P., Bellevue Group AG, Sofinnova Investments Inc., Verition Fund Management LLC, and Bessemer Group Inc..
View insider buying and selling activity for Homology Medicines
.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $11.26.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $509.15 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.